Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.
chronic myeloid leukemia
deep molecular response
optimal strategies
treatment-free remission
tyrosine kinase inhibitors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
01
2020
accepted:
05
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), through the achievement of a DMR, is increasingly regarded as a feasible treatment goal in many CML patients. However, only nilotinib has approval in this setting and a number of controversial aspects remain regarding treatment choices and timings, predictive factors, patient communication, and optimal strategies to achieve successful TFR. This narrative review aims to provide a comprehensive overview on how to optimize the path to DMR and TFR in patients with CML, and discusses recent data and future directions.
Identifiants
pubmed: 32582549
doi: 10.3389/fonc.2020.00883
pmc: PMC7280484
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
883Informations de copyright
Copyright © 2020 Annunziata, Bonifacio, Breccia, Castagnetti, Gozzini, Iurlo, Pregno, Stagno and Specchia.
Références
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
PLoS One. 2019 Mar 21;14(3):e0214305
pubmed: 30897165
Lancet Haematol. 2019 Jul;6(7):e375-e383
pubmed: 31201085
Am J Hematol. 2016 Nov;91(11):E480-E481
pubmed: 27467708
Leukemia. 2019 Oct;33(10):2358-2364
pubmed: 31455852
J Cancer Res Clin Oncol. 2019 Jun;145(6):1645-1650
pubmed: 30941573
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Leukemia. 2016 May;30(5):1044-54
pubmed: 26837842
J Cancer Res Clin Oncol. 2017 May;143(5):843-850
pubmed: 28083711
Blood. 2013 May 9;121(19):3818-24
pubmed: 23515925
Eur J Cancer. 2013 Oct;49(15):3242-6
pubmed: 23876833
Oncologist. 2019 May;24(5):e188-e195
pubmed: 31019020
Blood. 2014 Jul 31;124(5):729-36
pubmed: 24948656
Leukemia. 2018 Dec;32(12):2572-2579
pubmed: 30315232
J Natl Compr Canc Netw. 2019 May 1;17(5.5):611-613
pubmed: 31117031
J Hematol Oncol. 2019 Apr 23;12(1):39
pubmed: 31014376
Patient Prefer Adherence. 2018 Jun 15;12:1025-1032
pubmed: 29942119
J Clin Oncol. 2010 Mar 10;28(8):1429-35
pubmed: 20142590
Leuk Lymphoma. 2018 Feb;59(2):406-415
pubmed: 28617066
Blood Adv. 2019 Dec 23;3(24):4280-4290
pubmed: 31869412
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Haematologica. 2014 Sep;99(9):1441-7
pubmed: 24837466
Haematologica. 2017 Aug;102(8):1368-1377
pubmed: 28522576
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):375-379
pubmed: 29753691
Leukemia. 2016 Jan;30(1):57-64
pubmed: 26437782
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Clin Cancer Res. 2019 Nov 15;25(22):6606-6613
pubmed: 31292142
Cancer. 2017 Nov 15;123(22):4403-4410
pubmed: 28743166
Leukemia. 2020 Apr;34(4):1052-1061
pubmed: 31768016
Curr Hematol Malig Rep. 2019 Feb;14(1):56-61
pubmed: 30645715
Leukemia. 2017 Jul;31(7):1525-1531
pubmed: 28218239
J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596
pubmed: 28364360
Hematol Oncol. 2019 Dec;37(5):652-654
pubmed: 31321792
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
N Engl J Med. 2019 Dec 12;381(24):2315-2326
pubmed: 31826340
N Engl J Med. 2010 Dec 23;363(26):2511-21
pubmed: 21175313
Blood. 2019 Jul 4;134(1):85-89
pubmed: 30967368
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Lancet Haematol. 2015 Jan;2(1):e37-46
pubmed: 26687426
Int J Hematol. 2018 Oct;108(4):355-364
pubmed: 28689264
Cancer Med. 2019 May;8(5):2041-2055
pubmed: 30950237
Leukemia. 2016 Sep;30(9):1853-60
pubmed: 27133821
Br J Haematol. 2019 Nov;187(3):337-346
pubmed: 31271217
Haematologica. 2019 Aug;104(8):1589-1596
pubmed: 30819917
Leuk Lymphoma. 2020 Mar;61(3):650-659
pubmed: 31647335
Am J Hematol. 2017 Dec;92(12):E668-E670
pubmed: 28960424
Leukemia. 2017 May;31(5):1108-1116
pubmed: 27890936
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Br J Haematol. 2019 Jul;186(1):54-59
pubmed: 30864168
Front Pharmacol. 2023 May 26;14:1194712
pubmed: 37305536
Cancer. 2017 May 15;123(10):1791-1799
pubmed: 28026860
Am J Hematol. 2015 Oct;90(10):910-4
pubmed: 26178642
Front Oncol. 2019 May 14;9:372
pubmed: 31139566
Leuk Res. 2018 Nov;74:89-96
pubmed: 30340199
Med Oncol. 2017 Jun;34(6):104
pubmed: 28444623
Br J Haematol. 2017 May;177(4):578-587
pubmed: 28340283
Leuk Lymphoma. 2019 May;60(5):1116-1125
pubmed: 30481083
Haematologica. 2010 Aug;95(8):1415-9
pubmed: 20305139
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Curr Hematol Malig Rep. 2019 Aug;14(4):337-345
pubmed: 31197525
Nat Rev Clin Oncol. 2017 Mar;14(3):141-154
pubmed: 27752053
Lancet Haematol. 2015 Dec;2(12):e528-35
pubmed: 26686407
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94
pubmed: 27101984
J Cancer Res Clin Oncol. 2018 May;144(5):945-954
pubmed: 29468438
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
Front Psychol. 2019 Feb 20;10:329
pubmed: 30842749
J Cancer Res Clin Oncol. 2017 Jul;143(7):1167-1176
pubmed: 28289895
Leukemia. 2017 Nov;31(11):2529-2531
pubmed: 28862704
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
Blood. 2016 Jul 7;128(1):17-23
pubmed: 27013442
J Clin Oncol. 2014 Sep 1;32(25):2821-3
pubmed: 25071107
Leuk Res. 2015 Oct;39(10):1055-9
pubmed: 26282944
Blood. 2016 Mar 10;127(10):1269-75
pubmed: 26729897
Blood Cancer J. 2018 Dec 2;8(10):91
pubmed: 30504932
Blood. 2014 Jun 19;123(25):3951-62
pubmed: 24778155
Hematology. 2016 May;21(4):213-7
pubmed: 26183593
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135
pubmed: 30181422
Mediterr J Hematol Infect Dis. 2020 Sep 01;12(1):e2020066
pubmed: 32952977
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986
Br J Haematol. 2019 Nov;187(4):543-545
pubmed: 31584727